BetaGlue Therapeutics

ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics

Brings 2024 Funding Round Total to €24m 16 December 2024 — Milan, Italy — BetaGlue Therapeutics S.p.A, an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®, announced today that the ENEA-Tech and Biomedical Foundation (“ENEA-Tech”) has invested €6m bringing the total raised…
BetaGlue Therapeutics SpA. Piazzetta Umberto Giordano 4, 20122 Milan, Italy